News and Announcements
Analytica Chairman’s Address, Annual General Meeting & Presentation
- Published November 24, 2016 11:43AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
24th November 2016, ASX Announcement
Over the last 12 months the Analytica team has worked tirelessly to put us closer to a position to enable execution of a global licence deal for both the PeriCoach and the ASB.
As stated at the last AGM Analytica’s strategy to commercialize the PeriCoach and the ASB was to partner with multinational medical device companies. We see ourselves as an R & D company, not a marketing company.
After talking to multinational medical device companies, US based Investment Bankers and external consultants we soon realised that Analytica needed to do several things in order to get the best possible deal on our terms.
To view the full announcement, please click on the button below.
To view the full Presentation, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
